Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note published on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a research report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target for the company.

Lipocine Price Performance

NASDAQ LPCN opened at $5.10 on Friday. The company has a market cap of $27.27 million, a price-to-earnings ratio of -6.71 and a beta of 1.24. The stock’s fifty day moving average price is $5.10 and its 200 day moving average price is $5.57. Lipocine has a 1 year low of $2.40 and a 1 year high of $11.79.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. Research analysts expect that Lipocine will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new position in Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent SEC filing. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.